Session Time: 1:45pm-3:15pm
Location: Agora 3 West, Level 3
Objective: The concentrations of NAA, Cr, mIns, and Glx are identified as putative neurochemical markers of CI in patients with PD.
Background: On the basis analysis of MRS data we propose markers for the characteristics of the local metabolic state of the brain in patients with PD and different level of CI.
Method: Three groups of PD-patients with various cognitive statuses are studied by MRI and 1H MRS with 1.5T SIGNA HDxt (GE). The 1st group (DPDG) consists of 13 PD-patients with dementia (MMSE<25). The 2nd group (CIPDG) consists of 15 PD-patients with mild CI (30≥MMSE≥25).The 3rd group (NPDG) includes 12 PD-patients with normal cognitive function (MMSE≥30). Spectra are recorded in both hemispheres in the frontal lobe (FL), and in the putamen (P).
Results: From the spectra the content (in mM) of NAA, Cr, Cho, mIns, Glx=Glu+Gln, and the ratios:NAA/Cho, NAA/Cr, Cho/Cr, mIns/Cr, and Glx/Cr are obtained. For the patients of DPDG the significant decrease of NAA, Cr, and Glx, and increase of Cho, and mIns content in sampled regions are observed. In P the values NAA/Cr ratios in DPDG and CIPDG are significantly lower than in the NPDG, and Cho/Cr ratios higher than in patients of NPDG. Concentration of NAA in P:(6.81+-1.8), (7.62+-1.4), (7.82+-1.3) in DPDG, CIPDG, and NPDG, respectively, and the ratios of NAA/Cr decrease with the grade of CI. Concentrations of mIns in FL: (4.23+-0.79), (3.69+-0.62), (3.43+-0.83) in DPDG, CIPDG, and NPDG, respectively, and mIns/Cr increase with the grade of CI. For all groups of patients in any regions of the brain there is no dependence between NAA/Cr, Cho/Cr, mIns/Cr ratios and motor disability or disease duration, and CI. Concentrations of Glx in the FL is more pronounced, than other metabolites:(8.1+-1.9), (9.32+-1.6), (10.6+-1.8) in DPDG, CIPDG, and NPDG, respectively, and Glx/Cr decrease with the grade of CI. Concentration of Glx in the BG: (6.34+-1.4), (7.93+-0.9), (9.46+-1.2) in DPDG, CIPDG, and NPDG. We have found the progressive decreasing Glx-content in the FL and in P for the patient of NPDG, CIPDG, DPDG, that is associated with poorer cognitive function.
Conclusion: Concentration of Glx in the FL, and in P is indicator of neuronal loss and dysfunction, and may be useful putative biomarker of CI in patients with PD.
References: 1. Sebastiano Galantucci, Federica Agosta, Elka Stefanova et al. Structural brain connectome and cognitive impairment in Parkinson Disease. – Radiology. – Vol 283. – No.2. (2017) 2. Xueling Suo, Du Lei, Nannan Li, et al. Functional brain connectome and its relation to Hohen and Yahr stage in Parkinson Disease. – Radiology. – Vol. 285. – No.3 (2017). 3. Gong-Jun JI, Panpan Hu, Ting-Ting Liu, et al. Functional connectivity of the corticobasal ganglia-talamocortical network in Parkinson Disease:a systematic review and meta-analysis with cross-validation. – Radiology. – Vol.287. – No. 3 (2017). 4. Leslie Mazuel, Carine Chassain, Betty Jean, et al. Proton MR spectroscopy for diagnosis and evaluation of treatment efficacy in Parkinson Disease. – Radiology. Vol. 278. – No. 2 (2016).
To cite this abstract in AMA style:I. Karaban', N. Karasevich, Z. Rozhkova. Biomarkers of the Level of Cognitive Impairment (CI) in patients with Parkinson’s Disease (PD): MRS study [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/biomarkers-of-the-level-of-cognitive-impairment-ci-in-patients-with-parkinsons-disease-pd-mrs-study/. Accessed December 7, 2023.
« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/biomarkers-of-the-level-of-cognitive-impairment-ci-in-patients-with-parkinsons-disease-pd-mrs-study/